Abemaciclib is a kinase inhibitor used to treat adult patients with hormone receptor (HR)- positive, human epidermal growth factor receptor 2 (HER2)-negative advanced, or metastatic breast cancer with disease progression following endocrine therapy or prior to chemotherapy in the metastatic setting. Abemaciclib is a cyclin-dependent kinase (CDK) inhibitor that targets CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway. When abemaciclib inhibits CDK4 and 6, retinoblastoma (Rb) protein phosphorylation is inhibited, ultimately arresting the cell cycle in the G1 phase. This leads to suppression of DNA synthesis, blocks cell cycle progression from G1 to S phase, ultimately causing inhibition of cancer cell growth and apoptosis.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Abemaciclib, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.